AQSE Rule 4.14
Ananda is developing a range of cannabinoid-based medicines targeting the treatment of complex, chronic inflammatory pain conditions. Our goals are to deliver:
- The highest quality cannabinoid medicines, manufactured in the UK to the highest pharmaceutical standards
- Robust clinical trials by partnering with world leading researchers
- Patented and licenced cannabinoid medicines that are available on the NHS
Ananda has a team comprised of seasoned, successful and driven entrepreneurs together with best-in-class operational and technical staff to deliver on our goals.
Shareholders’ attention is drawn to the risk factors set out in Part II of the Company’s Admission Document dated 21 June 2018 and available on this website at the following link: Admission Document.